Synthesis, Spectral Characterization, and Antibacterial Evaluation of Novel Isatin-Based 1,2,4-Triazole Derivatives

Zainab Adnan Shawkat

doi:10.51699/cajmns.v7i1.3080

Authors

Zainab Adnan Shawkat University of Kirkuk, College of Pharmacy, Department of Pharmaceutical Chemistry, Kirkuk, Iraq

DOI:

https://doi.org/10.51699/cajmns.v7i1.3080

Keywords:

Include Cytotoxicity, Isatin Derivatives, 1,2,4-Triazoles, Hybrid Compounds, Biofilm Inhibition, Antimicrobial Resistance, Minimal Inhibitory Concentration

Abstract

Antibiotic resistance remains a major global public health challenge, necessitating the development of innovative and improved therapeutic strategies. Molecular hybridization could serve as a strategy to develop multi-target antibacterial agents capable of overcoming existing resistance mechanisms. The objective of this investigation was to design, synthesize, and assess the antibacterial activity of two novel isatin-1,2,4-triazole hybrid substances against clinically significant multidrug-resistant strains of bacteria. Synthesized hybrid compounds (ST1 and ST2) through the condensation of isatin with various amino acid derivatives. The synthesis procedure was conducted within a controlled laboratory environment to ensure reproducibility. Infrared Fourier transform (FTIR), proton (^1H NMR) spectroscopy using nuclear magnetic resonance and carbon (^13C NMR) nuclear magnetic resonance spectroscopy were employed to verify the chemical structures of the synthesized compounds. We employed the zone of inhibition assay to evaluate the efficacy of ST1 and ST2 in eliminating clinical isolates for Klebsiella pneumoniae and Acinetobacter spp. Furthermore, the MIC (minimum inhibitory concentration) and the MBC (minimum bactericidal concentration) were determined to assess antibacterial efficacy in a more comprehensive manner. We also examined the compounds' capacity to inhibit biofilm formation to assess their antibiofilm activity. The MTT assay was also employed to evaluate the cytotoxicity of the synthesized compounds on HEK-293 cell lines to assess their safety. Antibacterial activities of ST2 were even superior to that of ST1. For ST2, the inhibition zones were 14.2-15.8 mm at 32-64 mg/ml and MIC was as low as 16-32 mg/ml. Antibacterial activity indices were 6.1 for ST1 and 12.2 for ST2, suggesting the more pronounced effect of ST2 on tested bacteria. Both compounds inhibited biofilm formation. Percentage of biofilms inhibition by ST2 58–62% versus ST1: 35–38%. The activity against the studied bacterial isolates was augmented when these synthetic compounds and antibiotics were used in combination. The isatin-1,2,4-triazole hybrids identified in this study are interesting scaffolds for the creation of next-generation antimicrobials targeting a range of molecular pathways. ST2, in particular, has the potential to be developed and optimised as a treatment for drug-resistant diseases.

References

World Health Organization, Bacterial Pathogens of Public Health Importance to Guide R&D and Strategies to Prevent and Control Antimicrobial Resistance. Geneva, Switzerland: WHO, May 17, 2024, ISBN: 978-92-4-009346-1.

A. Kumar, Y. Rohila, V. Kumar, and K. Lal, “A mini review on pharmacological significance of isatin-1,2,3-triazole hybrids,” Curr. Top. Med. Chem., vol. 23, no. 10, pp. 833–847, 2023, doi: 10.2174/1568026623666230202160925.

Y. Rohila et al., “A comprehensive review of the diverse spectrum activity of 1,2,3-triazole-linked isatin hybrids,” Chem. Biodivers., vol. 21, no. 4, Art. no. e202301612, 2024, doi: 10.1002/cbdv.202301612.

Centers for Disease Control and Prevention, Antibiotic Resistance Threats in the United States, 2023. Atlanta, GA, USA: CDC, 2023.

E. Tacconelli et al., “Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis,” Lancet Infect. Dis., vol. 18, no. 3, pp. 318–327, 2018, doi: 10.1016/S1473-3099(17)30753-3.

World Health Organization, 77th World Health Assembly Resolution WHA77: Antibiotic Resistance—Accelerate Research and Innovation. Geneva, Switzerland: WHO, 2024.

L. Maiuolo et al., “1,2,3-Triazole hybrids containing isatins and phenolic moieties: Regioselective synthesis and molecular docking studies,” Molecules, vol. 29, no. 7, Art. no. 1556, 2024, doi: 10.3390/molecules29071556.

A. Thakur et al., “Isatin-based 1,2,3-triazole derivatives as antimicrobial agents: Synthesis, in silico docking and MD simulations,” Bioorg. Chem., vol. 134, Art. no. 106388, 2024, doi: 10.1016/j.bioorg.2023.106388.

A. Kumar et al., “Antimicrobial, antibiofilm, docking, DFT and MD studies on click-derived isatin-thiosemicarbazone-1,2,3-triazoles,” J. Biomol. Struct. Dyn., vol. 42, no. 19, pp. 9919–9938, 2024, doi: 10.1080/07391102.2023.2253912.

A. Tahghighi and P. Azerang, “Click chemistry beyond metal-catalyzed cycloaddition as a remarkable tool for green synthesis of antifungal medications,” Chem. Biol. Drug Des., vol. 103, no. 6, Art. no. e14555, 2024, doi: 10.1111/cbdd.14555.

R. Khandelwal et al., “Recent advances in triazole synthesis via click chemistry: Pharmacological applications,” Bioorg. Med. Chem. Lett., vol. 112, Art. no. 129927, 2024, doi: 10.1016/j.bmcl.2024.129927.

N. G. Pandit et al., “Synthesis and anti-inflammatory activity evaluation of novel triazolyl-isatin hybrids,” Bioorg. Med. Chem. Lett., vol. 26, no. 10, pp. 2476–2480, 2016, doi: 10.1016/j.bmcl.2016.03.107.

M. Shaaban et al., “Tackling microbial resistance with isatin-decorated thiazole derivatives,” ChemMedChem, vol. 17, no. 18, Art. no. e202200300, 2022, doi: 10.1002/cmdc.202200300.

M. Marzi et al., “A recent overview of 1,2,3-triazole-containing hybrids as novel antifungal agents,” J. Chem., Art. no. 7884316, 2022, doi: 10.1155/2022/7884316.

M. Bayat, M. Imani, and D. Zareyee, “Urea-thiazole/benzothiazole hybrids with a triazole linker,” Bioorg. Chem., vol. 116, Art. no. 105326, 2021, doi: 10.1016/j.bioorg.2021.105326.

V. Kumar et al., “Isatin Schiff base linked 1,2,3-triazole hybrids: Synthesis and in silico studies,” Chem. Biodivers., vol. 21, no. 7, Art. no. e202400569, 2024, doi: 10.1002/cbdv.202400569.

V. Kumar et al., “Thiazole-isatin-1,2,3-triazole hybrids: Docking and dynamics for DNA gyrase inhibition,” Chem. Biodivers., vol. 21, no. 10, Art. no. e202400914, 2024, doi: 10.1002/cbdv.202400914.

S. S. Gholap et al., “Synthesis, antifungal activities, molecular docking and molecular dynamic studies of novel quinoxaline-triazole compounds,” ACS Omega, vol. 8, no. 31, pp. 28308–28320, 2023, doi: 10.1021/acsomega.3c02797.

A. Krishnan et al., “Electrochemically generated copper(I)-catalyzed click chemistry,” Eur. J. Org. Chem., vol. 26, no. 19, Art. no. e202201405, 2023, doi: 10.1002/ejoc.202201405.

S. Tiwari et al., “Click-chemistry-inspired synthesis of 1,2,3-triazole fused chromenes,” Bioorg. Chem., vol. 147, Art. no. 107380, 2024, doi: 10.1016/j.bioorg.2024.107380.

S. M. Sondhi, M. Dinodia, and A. Kumar, “Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin,” Indian J. Chem., vol. 39B, pp. 94–103, 2000.

M. Patel, A. Pandya, and R. Patel, “Synthesis and antifungal activity of novel triazole compounds,” J. Chem. Res., vol. 38, no. 8, pp. 487–492, 2014, doi: 10.3184/174751914X14081871159554.

P. Chemmugil et al., “Synthesis, characterization, and molecular docking of isatin derivatives,” J. Mol. Struct., vol. 1244, Art. no. 131227, 2021, doi: 10.1016/j.molstruc.2021.131227.

M. M. Sheha et al., “Synthesis, in vivo anti-inflammatory activity, and molecular docking studies of new isatin derivatives,” Int. J. Med. Chem., Art. no. 2575303, 2016, doi: 10.1155/2016/2575303.

J. Molla et al., “Synthesis and antimicrobial evaluation of new acetylenic Mannich bases of isatin–thiazole derivatives,” Iraqi J. Pharm. Sci., vol. 30, no. 2, pp. 194–205, 2021, doi: 10.31351/vol30iss2pp194-205.

B. Srinivas et al., “Anti-tubercular activity and molecular docking studies of indolizine derivatives,” Bioorg. Med. Chem., vol. 44, Art. no. 116295, 2021, doi: 10.1016/j.bmc.2021.116295.

J. Xu et al., “Enantioselective copper-catalyzed azidation/click cascade reaction,” Nat. Commun., vol. 15, Art. no. 3313, 2024, doi: 10.1038/s41467-024-49313-x.

M. S. Mohamed et al., “Synthesis and antimicrobial evaluation of new fenamate-isatin hybrids,” J. Mol. Struct., vol. 1274, Art. no. 134567, 2023, doi: 10.1016/j.molstruc.2022.134567.

J. Wang et al., “Copper(I)-catalyzed click chemistry in deep eutectic solvent,” RSC Adv., vol. 13, pp. 10844–10853, 2023, doi: 10.1039/D3RA01844J.

A. M. Asiri et al., “Synthesis and molecular docking studies of novel isatin-thiosemicarbazone derivatives,” J. Mol. Struct., vol. 1202, Art. no. 127285, 2020, doi: 10.1016/j.molstruc.2019.127285.

A. Pasieka, M. Kuchta, and T. Gajda, “Click chemistry and targeted degradation,” ChemMedChem, vol. 18, no. 18, Art. no. e202300422, 2023, doi: 10.1002/cmdc.202300422.

A. Vaidya et al., “Click chemistry inspired syntheses of amide linked 1,2,3-triazoles,” Res. Chem. Intermed., vol. 49, no. 7, pp. 3089–3115, 2023, doi: 10.1007/s11164-023-05008-4.

M. Jaiswal et al., “Growing impact of intramolecular click chemistry in organic synthesis,” Chem. Rec., vol. 23, no. 7, Art. no. e202300167, 2023, doi: 10.1002/tcr.202300167.

W. Cardona-Galeano et al., “Synthesis and chemopreventive potential of 5-FU/genistein hybrids,” Pharmaceuticals, vol. 15, no. 10, Art. no. 1299, 2022, doi: 10.3390/ph15101299.

V. Kumar et al., “Synthesis, characterization, antimicrobial and in silico studies of isatin Schiff base linked 1,2,3-triazole hybrids,” Chem. Biodivers., vol. 21, no. 6, Art. no. e202400569, 2024, doi: 10.1002/cbdv.202400569.

D. Rohila et al., “A comprehensive review of the diverse spectrum activity of 1,2,3-triazole-linked isatin hybrids,” Chem. Biodivers., vol. 21, no. 5, Art. no. e202301612, 2024, doi: 10.1002/cbdv.202301612.

A. Singh et al., “Synthesis, antimicrobial, antibiofilm and computational studies of isatin-semicarbazone tethered 1,2,3-triazoles,” Bioorg. Med. Chem., vol. 82, Art. no. 117226, 2023, doi: 10.1016/j.bmc.2023.117226.

A. Kumar et al., “Concomitant inhibition of dual-species biofilms by triazole-based small-molecule inhibitors,” Pharmaceutics, vol. 16, no. 12, Art. no. 1570, 2024, doi: 10.3390/pharmaceutics16121570.

“Inhibition of apoptosis and biofilm formation in Candida auris by click-synthesized triazole-bridged quinoline derivatives,” RSC Adv., vol. 14, no. 30, pp. 21234–21245, 2024, doi: 10.1039/D4RA03728F.

N. Anwar et al., “Triazole-based isatin derivatives as potential inhibitors of cancer-promoting kinases,” 2021.

K. L. Vine et al., “Therapeutic outcomes of isatin and its derivatives against multiple diseases,” 2022.

M. Bhat et al., “Isatin-1,2,3-triazole derivatives: Synthesis and biological evaluation,” 2023.